More recently, Weisberg and collaborators [101] analysed the dependency on BRD9 in a variety of hematological cancers, including MM, ALL and AML, using novel small molecule inhibitors (EA-89-YM35), degraders (QA-68-ZU81), and RNA interference. Here, BRD9 is linked to Miyoshi myopathy.